Introduction:
Catalent Pharma Solutions made an announcement to investment US$5 million towards construction of a new drug development and modified release centre of excellence at its Somerset site.
Features:
Catalent Pharma Solutions is planning to invest US$5 million to establish a new drug development centre of excellence at its Somerset site.
The focus of this investment is to develop a preclinical and clinical phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules.
The various advanced technologies and development solutions such as modified release formulation, bioavailability solutions, OptiMelt hot melt extrusion (HME) technology going to be integrated into the new development centre of excellence.
The Somerset facility centre comprises state-of-the-art laboratories, pilot and clinical scale equipment including HME and fluid bed processing.
The new drug facility center specialises in coating technologies, capsules, tablets, minitablets, and multi-particulates.
In addition, the development centre will also offer smooth transfers of later stage clinical trials using compatible, scalable equipment to other integrated commercial manufacturing units of Catalent Pharma spread across countries.
Specifications:
| Name | Catalent Pharma Solutions |
| Location | Somerset, New Jersey |
| Type | Expansion |
| Estimated Budget | US $5 million |
| Parties involved | Catalent Pharma Solutions |
